Identification of PCPE-2 as the endogenous specific inhibitor of human BMP-1/tolloid-like proteinases.
Sandrine Vadon-Le GoffAgnès TessierManon NapoliCindy DieryckxJulien BauerMélissa DussoyerPriscillia LagoutteCélian PeyronnelLucie EssayanSvenja KleiserNicole TueniEmmanuel BettlerNatacha MarianoElisabeth Errazuriz-CerdaCarole Fruchart GaillardFlorence RuggieroChristoph Becker-PaulyJean-Marc AllainLeena Bruckner-TudermanAlexander NyströmCatherine MoaliPublished in: Nature communications (2023)
BMP-1/tolloid-like proteinases (BTPs) are major players in tissue morphogenesis, growth and repair. They act by promoting the deposition of structural extracellular matrix proteins and by controlling the activity of matricellular proteins and TGF-β superfamily growth factors. They have also been implicated in several pathological conditions such as fibrosis, cancer, metabolic disorders and bone diseases. Despite this broad range of pathophysiological functions, the putative existence of a specific endogenous inhibitor capable of controlling their activities could never be confirmed. Here, we show that procollagen C-proteinase enhancer-2 (PCPE-2), a protein previously reported to bind fibrillar collagens and to promote their BTP-dependent maturation, is primarily a potent and specific inhibitor of BTPs which can counteract their proteolytic activities through direct binding. PCPE-2 therefore differs from the cognate PCPE-1 protein and extends the possibilities to fine-tune BTP activities, both in physiological conditions and in therapeutic settings.
Keyphrases
- extracellular matrix
- binding protein
- mesenchymal stem cells
- endothelial cells
- bone regeneration
- air pollution
- transcription factor
- papillary thyroid
- protein protein
- squamous cell carcinoma
- heat shock
- amino acid
- transforming growth factor
- oxidative stress
- signaling pathway
- pluripotent stem cells
- small molecule
- bone marrow
- induced pluripotent stem cells
- epithelial mesenchymal transition
- bone loss